JP2004502408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502408A5 JP2004502408A5 JP2001572548A JP2001572548A JP2004502408A5 JP 2004502408 A5 JP2004502408 A5 JP 2004502408A5 JP 2001572548 A JP2001572548 A JP 2001572548A JP 2001572548 A JP2001572548 A JP 2001572548A JP 2004502408 A5 JP2004502408 A5 JP 2004502408A5
- Authority
- JP
- Japan
- Prior art keywords
- altered peptide
- peptide
- cells
- peptides
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 101001013022 Homo sapiens Migration and invasion enhancer 1 Proteins 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010066345 MHC binding peptide Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000900711 Mus musculus GRB2-related adaptor protein 2 Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19446300P | 2000-04-04 | 2000-04-04 | |
| PCT/US2001/010855 WO2001074859A2 (en) | 2000-04-04 | 2001-04-04 | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502408A JP2004502408A (ja) | 2004-01-29 |
| JP2004502408A5 true JP2004502408A5 (enExample) | 2008-05-22 |
Family
ID=22717696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572548A Pending JP2004502408A (ja) | 2000-04-04 | 2001-04-04 | 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7268207B2 (enExample) |
| EP (1) | EP1272636B8 (enExample) |
| JP (1) | JP2004502408A (enExample) |
| CN (2) | CN101643732A (enExample) |
| AT (1) | ATE404669T1 (enExample) |
| AU (2) | AU2001253119B2 (enExample) |
| CA (1) | CA2413211A1 (enExample) |
| DE (1) | DE60135315D1 (enExample) |
| NZ (1) | NZ522282A (enExample) |
| WO (1) | WO2001074859A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413211A1 (en) | 2000-04-04 | 2001-10-11 | University Of Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| US7135278B1 (en) | 2000-09-29 | 2006-11-14 | University Of Rochester | Method of screening for therapeutics for infectious diseases |
| US20020164346A1 (en) * | 2001-02-14 | 2002-11-07 | Nicolette Charles A. | Altered peptide ligands |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003104428A2 (en) * | 2002-01-21 | 2003-12-18 | Vaccinex, Inc. | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| WO2004087058A2 (en) * | 2003-03-28 | 2004-10-14 | Vaccinex, Inc. | Targeted mhc class i alpha3 vaccine delivery systems |
| WO2005099361A2 (en) * | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| CA2548180C (en) * | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| WO2005106044A1 (en) * | 2004-04-23 | 2005-11-10 | Exagen Diagnostics, Inc. | Compositions and methods for breast cancer prognosis |
| AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
| JP5357782B2 (ja) * | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節 |
| WO2009045370A2 (en) | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| JP5690593B2 (ja) | 2007-12-26 | 2015-03-25 | ヴァクシネックス， インコーポレイテッド | 抗ｃ３５抗体併用療法および方法 |
| AU2010203451B2 (en) | 2009-01-08 | 2016-06-30 | Albert Einstein College Of Medicine, Inc. | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| EP2413968B1 (en) * | 2009-04-01 | 2017-05-17 | The University Of British Columbia | Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses |
| WO2011038142A2 (en) * | 2009-09-24 | 2011-03-31 | The Regents Of The University Of California | Bladder cancer specific ligand peptides |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| KR102883915B1 (ko) * | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| WO2019050994A1 (en) * | 2017-09-05 | 2019-03-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| US12359253B2 (en) | 2018-04-09 | 2025-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Method of in situ gene sequencing |
| KR102318018B1 (ko) | 2019-07-05 | 2021-10-28 | 한국생산기술연구원 | 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드 |
| US20230109070A1 (en) * | 2019-10-18 | 2023-04-06 | The Board of Trustees og the Leland Standford Junior University | Clinical- and industrial-scale intact-tissue sequencing |
| CN115407064B (zh) * | 2021-05-26 | 2025-09-23 | 复旦大学附属肿瘤医院 | 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途 |
| US20240409582A1 (en) * | 2022-08-23 | 2024-12-12 | The University of North Texas Health Sciences Cente | Design and characterization of inhibitory peptides (ipeps) derived from of mien 1 protein sequence |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0581600A (ja) * | 1991-04-18 | 1993-04-02 | Fujitsu Ltd | 双曲線航法システムにおけるシステム監視処理方式 |
| SG52492A1 (en) | 1992-08-07 | 1998-09-28 | Cytel Corp | Hla binding peptides and their uses |
| JP3908271B2 (ja) | 1993-03-05 | 2007-04-25 | エピミューン，インコーポレイティド | Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用 |
| US5856131A (en) * | 1997-02-24 | 1999-01-05 | Incyte Pharmaceuticals, Inc. | Human selenoprotein |
| US7026447B2 (en) * | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
| AU2010699A (en) * | 1997-12-24 | 1999-07-19 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse |
| WO1999037775A2 (en) | 1998-01-26 | 1999-07-29 | Genquest, Inc. | Compositions and methods for detecting and treating breast cancer |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| AU1807401A (en) | 1999-11-30 | 2001-06-12 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
| CA2413211A1 (en) * | 2000-04-04 | 2001-10-11 | University Of Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| CA2406378A1 (en) * | 2000-04-12 | 2001-10-25 | University Of Rochester | Targeted vaccine delivery systems |
| US20050196755A1 (en) | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| CA2429544C (en) | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2003104428A2 (en) | 2002-01-21 | 2003-12-18 | Vaccinex, Inc. | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| WO2005099361A2 (en) * | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| CA2548180C (en) | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
-
2001
- 2001-04-04 CA CA002413211A patent/CA2413211A1/en not_active Abandoned
- 2001-04-04 AU AU2001253119A patent/AU2001253119B2/en not_active Ceased
- 2001-04-04 EP EP01926595A patent/EP1272636B8/en not_active Expired - Lifetime
- 2001-04-04 NZ NZ522282A patent/NZ522282A/en unknown
- 2001-04-04 DE DE60135315T patent/DE60135315D1/de not_active Expired - Lifetime
- 2001-04-04 AT AT01926595T patent/ATE404669T1/de not_active IP Right Cessation
- 2001-04-04 JP JP2001572548A patent/JP2004502408A/ja active Pending
- 2001-04-04 WO PCT/US2001/010855 patent/WO2001074859A2/en not_active Ceased
- 2001-04-04 CN CN200910007590A patent/CN101643732A/zh active Pending
- 2001-04-04 US US09/824,787 patent/US7268207B2/en not_active Expired - Fee Related
- 2001-04-04 AU AU5311901A patent/AU5311901A/xx active Pending
- 2001-04-04 CN CNA018178049A patent/CN1610743A/zh active Pending
-
2006
- 2006-11-20 US US11/601,669 patent/US20070081942A1/en not_active Abandoned
-
2009
- 2009-02-26 US US12/393,860 patent/US7910551B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201564B2 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| US11859015B2 (en) | Immunogenic WT-1 peptides and methods of use thereof | |
| JPWO2007097358A1 (ja) | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| PT1650221E (pt) | Novos compostos | |
| JP2014533095A5 (enExample) | ||
| JPWO2020071551A5 (enExample) | ||
| US20050048068A1 (en) | Therapeutic compounds for ovarian cancer | |
| US6579970B2 (en) | Therapeutic anti-cytomegalovirus compounds | |
| US7071294B1 (en) | Tumor antigen protein art-1 and tumor antigen peptide thereof | |
| JP2002538166A (ja) | Ｍｈｃクラスｉｉによって提示されるｍａｇｅ−３由来免疫原性ペプチドおよびその使用 | |
| CN105531368A (zh) | 肿瘤抗原肽 | |
| JP2003522195A (ja) | 肝細胞癌の治療のための方法及び組成物 | |
| JP2002539826A (ja) | 新規化合物 | |
| US6809179B1 (en) | Tumor-associated antigen (R11) | |
| WO2007039716A1 (en) | T cell epitopes from the 5t4 tumor associated antigen and their use in treatment of cancer | |
| US20040138135A1 (en) | Therapeutic compounds for ovarian cancer | |
| US7476535B2 (en) | TRP2 isoform TRP2-6b containing HLA-A2 restricted epitopes | |
| CA2387043A1 (en) | Colon-tumour-associated antigens | |
| EP2330122A1 (en) | OFA/iLRP derived modified peptide | |
| Seliger et al. | Cytotoxic T Cell Epitopes and Tissue | |
| HK40045843A (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| US20050059056A1 (en) | Antigenic gp100 (154-162) compounds for therapy and diagnosis and methods for using same | |
| WO2004039333A2 (en) | ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME | |
| US20020160959A1 (en) | Therapeutic compounds for ovarian cancer | |
| ZA200107445B (en) | CASB618 polynucleotides and polypeptides and their use. |